Nrc Health (NRC) valuation
Nrc Health P/E ratio history
Nrc Health trades at 99.3 times its earnings over the last twelve months and 23.0 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 16.8 (year to Dec 2024) to 52.3 (year to Dec 2019), with a median of 29.5.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $18.77 | $0.49 | 38.3 |
| Dec 31, 2024 | $17.64 | $1.05 | 16.8 |
| Dec 31, 2023 | $39.56 | $1.25 | 31.7 |
| Dec 31, 2022 | $37.30 | $1.27 | 29.4 |
| Dec 31, 2021 | $41.52 | $1.46 | 28.4 |
| Dec 31, 2020 | $42.75 | $1.45 | 29.5 |
| Dec 31, 2019 | $65.94 | $1.26 | 52.3 |
| Dec 31, 2018 | $38.14 | — | n/m |
| Dec 31, 2017 | $37.30 | — | n/m |
| Dec 31, 2016 | $19.00 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Nrc Health valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Nrc HealthNRC | $537M | 99.3 | 23.0 | 3.8 |
| Bright Minds BiosciencesDRUG | $539M | — | — | — |
| Sbc Medical GroupSBC | $543M | 11.0 | 10.6 | 3.1 |
| Puma BiotechnologyPBYI | $531M | 20.1 | — | 2.3 |
| Aclaris TherapeuticsACRS | $554M | — | — | 67.4 |
| Tactile Systems TechnologyTCMD | $520M | 21.5 | 17.6 | 1.5 |
| Mimedx GroupMDXG | $566M | — | 70.4 | 1.9 |
| ArvinasARVN | $507M | 32.8 | — | 1.6 |
| Sight SciencesSGHT | $507M | — | — | 6.1 |
| Peer median | 20.8 | 17.6 | 2.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NRC financials · NRC returns
No forecast, no recommendation. This page describes Nrc Health from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.